Metformin use and endometrial cancer survival

Nicole S. Nevadunsky, Anne Van Arsdale, Howard D. Strickler, Alyson Moadel, Gurpreet Kaur, Marina Frimer, Erin Conroy, Gary L. Goldberg, Mark H. Einstein

Research output: Contribution to journalArticle

85 Scopus citations

Abstract

Objective Impaired glucose tolerance and diabetes are risk factors for the development of uterine cancer. Although greater progression free survival among diabetic patients with ovarian and breast cancers using metformin has been reported, no studies have assessed the association of metformin use with survival in women with endometrial cancer (EC). Methods We conducted a single-institution retrospective cohort study of all patients treated for uterine cancer from January 1999 through December 2009. Demographic, medical, social, and survival data were abstracted from medical records and the national death registry. Overall survival (OS) was estimated using Kaplan-Meier methods. Cox models were utilized for multivariate analysis. All statistical tests were two-sided. Results Of 985 patients, 114 (12%) had diabetes and were treated with metformin, 136 (14%) were diabetic but did not use metformin, and 735 (74%) had not been diagnosed with diabetes. Greater OS was observed in diabetics with non-endometrioid EC who used metformin than in diabetic cases not using metformin and non-endometrioid EC cases without diabetes (log rank test (p = 0.02)). This association remained significant (hazard ratio = 0.54, 95% CI: 0.30-0.97, p < 0.04) after adjusting for age, clinical stage, grade, chemotherapy treatment, radiation treatment and the presence of hyperlipidemia in multivariate analysis. No association between metformin use and OS in diabetics with endometrioid histology was observed. Conclusion Diabetic EC patients with non-endometrioid tumors who used metformin had lower risk of death than women with EC who did not use metformin. These data suggest that metformin might be useful as adjuvant therapy for non-endometrioid EC.

Original languageEnglish (US)
Pages (from-to)236-240
Number of pages5
JournalGynecologic Oncology
Volume132
Issue number1
DOIs
StatePublished - Jan 1 2014

Keywords

  • Adjuvant therapy
  • Endometrial cancer
  • Metformin
  • Non-endometrioid
  • Retrospective cohort study

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Metformin use and endometrial cancer survival'. Together they form a unique fingerprint.

  • Cite this